RE: Clarification from BNC on Phase 3B It looks like Endo screwed us royally with their idiotic move to compare Urocidin to mitomycin C instead of with BCG as Bioniche had intended. My only question is whether this was an intentional stall tactic by Endo to bleed Bioniche and put us in a very weak financial positon. Really stupid move going against Mitomycin C, and Endo really sucks!
We can only hope that Endo will be forced to finance all the additional cost to move a new trial forward, but probably just wishful thinking.
Looks like Bioniche will have to make some sort of move to sell rights to one of their products, or partner up with an entity by moving a high profile product forward such as Oncocidin for human use with a big upfront payment for partnering rights. (Oncocidin is the highly potential immuotherapy drug that restores white blood cells in all chemo patients within 24 hours) . I think fund raising via more loans or dilution at this horrible stock price are not viable choices any more.